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AbstrAct
Objective Critically ill patients admitted to the intensive 
care unit (ICU) often develop atrial fibrillation (AF), with 
an incidence of around 5%. Stroke prevention in AF is 
well described in clinical guidelines. The extent to which 
stroke prevention is prescribed to ICU patients with AF 
is unknown. We aimed to determine the incidence of 
new- onset AF and describe stroke prevention strategies 
initiated on the ICU of our teaching hospital. Also, we 
compared mortality in patients with new- onset AF to 
critically ill patients with previously diagnosed AF and 
patients without any AF.
Methods This study was a retrospective cohort study 
including all admissions to the ICU of the Martini Hospital 
(Groningen, The Netherlands) in the period 2011 to 2016. 
Survival analyses were performed using these real- world 
data.
Results In total, 3334 patients were admitted to the ICU, 
of whom 213 patients (6.4%) developed new- onset AF. 
583 patients (17.5%) had a previous AF diagnosis, the 
other patients were in sinus rhythm. In- hospital mortality 
and 1- year mortality after hospital discharge were 
significantly higher for new- onset AF patients compared 
with patients with no history of AF or previously diagnosed 
AF. At hospital discharge, only 56.3% of the new- onset 
AF- patients eligible for stroke prevention received an 
anticoagulant. Anticoagulation was not dependent on 
CHA
2DS2- VASc score or other patient characteristics. 
An effect of anticoagulative status on mortality was not 
significant.
Conclusion AF is associated with increased mortality in 
critically ill patients admitted to the ICU. More guidance is 
needed to optimise anticoagulant treatment in critically ill 
new- onset AF patients.
IntROduCtIOn
Stroke prevention in atrial fibrillation (AF) 
is well described in clinical guidelines. The 
consensus is that oral anticoagulation should 
be initiated for stroke prevention in AF to 
improve outcomes related to stroke and 
mortality.1 2 Evidence on stroke prevention 
in critically ill patients is limited.3–5 Critically 
ill patients admitted to the intensive care 
unit (ICU) often develop AF, with an inci-
dence around 5% though this could rise to 
nearly 50% in patients with severe sepsis.4–9 
Acute pathophysiological changes such as 
inflammation, atrial oxidative stress, a high 
symptomatic tone and volume overload 
could be provoking factors for new- onset 
AF in critically ill patients.5 10 New onset of 
AF can be self- terminating in the critically 
ill phase though it could also be provoca-
tive for developing permanent AF. Evidence 
suggests that new- onset AF is associated with 
a higher mortality in critically ill patients 
admitted to the ICU.9 11 12 Since there is no 
clear consensus on which anticoagulative 
treatment is most appropriate to treat new- 
onset AF in critically ill patients, we aimed to 
determine the incidence of new- onset AF in 
a retrospective cohort study and analysed the 
Key questions
What is already known about this subject?
 ► Critically ill patients admitted to the intensive care 
unit (ICU) often develop atrial fibrillation (AF), with 
an incidence around 5% though this could rise to 
nearly 50% in specific subgroups. There is no clear 
consensus on which anticoagulative treatment is 
most appropriate to treat new- onset AF in critically 
ill patients,
What does this study add?
 ► In- hospital mortality and 1- year mortality was sig-
nificantly higher for new- onset atrial fibrillation 
patients compared with patients with no history of 
AF or previously diagnosed AF. Only 25.3% of the 
new- onset AF patients eligible for stroke preven-
tion received antiocoagulation at the ICU and this 
rose to over half at hospital discharge. An effect 
of anticoagulative status on mortality could not be 
demonstrated.
How might this impact on clinical practice?
 ► This study illustrates the lack of evidence, guidance 
and consensus on treatment in this specific patient 
group of critically ill new- onset AF patients. More re-
search could help to optimise clinical guidelines on 
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anticoagulation strategies that were initiated on the ICU 
of our teaching hospital. Also, we compared mortality in 
patients with new- onset AF compared with ICU patients 
without AF and also compared mortality in the new- onset 
AF patients to mortality in patients with previously diag-
nosed AF. Finally, we explored whether there is a relation 
between anticoagulation therapy and mortality in the 
new- onset AF patients.
MateRIals and MetHOds
Patients and procedure
The study was a retrospective cohort study including 
all hospitalisations to the ICU of the Martini Hospital 
(Groningen, The Netherlands) between 2011 and 2016.
Need for informed consent was waived by this Medical 
Ethics Committee. The format of the Minimal Data Set 
(MDS) of the National Intensive Care Evaluation (NICE) 
registry, a registry with all available data from all ICUs 
in the Netherlands,13 was used to collect all primary data 
and to determine the population size at our ICU. The 
data collected in the NICE registry was supplemented 
with additional data from the electronic health records 
(EHR) that was not captured in the NICE registry. This 
data consisted of hospital data from outside the ICU and 
some more specific data on medication use. To retrieve 
additional data from EHR, an interface (CTcue; CTcue 
BV; Amsterdam, The Netherlands) was used for a keyword 
text search for ‘atrial fibrillation’ and related synonyms 
for all patients admitted to the ICU within the research 
period. All data from the interface were matched with 
the hospital specific data in the format of the NICE MDS 
on the unique patient hospital identification number. 
The ICU hospital discharge letter was the primary source 
to determine if there was any AF diagnosed during ICU 
admission. Medical letters from the cardiology depart-
ment prior to the ICU admission, if available, were also 
analysed to determine a prior AF diagnosis. Furthermore, 
the ECG database containing short 12- lead ECG record-
ings (MUSE, General Electric) was used to screen for 
ECGs with AF during the period of ICU admission. Auto-
matic ECG AF diagnosis was confirmed by a cardiologist 
(RGT). The data was pseudonymised in the final data set. 
The diagnosis AF was denoted as present or absent on 
ICU admission to discriminate between no AF, known AF 
(pre- existing) and new- onset AF. Known AF also included 
patients with paroxysmal AF and patients with periods 
of sinus rhythm. Only the first ICU admission within 
the study period was used to determine the AF- related 
medical background and if AF was incident.
Patient and public involvement
Patients were not involved in the design and conduct of 
this study.
Outcomes
AF was confirmed with a 12- lead ECG. Categories of AF 
were defined as (1) ‘No AF’ with no previous AF diag-
nosed and no new diagnosis, (2) ‘Known AF’ with the 
diagnosis confirmed before ICU admission and (3) ‘New- 
onset AF’ with a first diagnosis during the ICU admission. 
Mortality was defined by checking if a date of decease 
was registered in the NICE MDS for decease during 
ICU admission and by checking if a date of decease was 
registered within the national database that includes the 
unique ‘citizen service number’. Mortality was deter-
mined within 360 days after hospital discharge following 
the ICU admission. In- hospital mortality was scored 
separately and defined as death by any cause that took 
place between ICU admission and the associated hospital 
discharge. Mortality for the maximum follow- up was also 
measured but not used for comparative survival analyses 
because of the high percentage of censored patients and 
the non- proportionality of the survival curves.
Covariates
Demographic data included age and sex category. Comor-
bidities present on admission were registered for all new- 
onset AF patients with the diagnosis mentioned in the 
discharge letter. The registered comorbidities included 
heart failure, hypertension, diabetes, prior stroke/TIA 
and vascular disease to calculate the CHA2DS2- VASc 
score. The need for stroke prevention was determined 
with the CHA2DS2- VASc score: men with a score of 1 or 
higher and women with a score of 2 or more were classi-
fied as eligible for stroke prevention. A minimal scoring 
method was used to calculate the bleeding risk through 
the HAS- BLED score, by adding information on renal 
disease, liver disease (cirrhosis), prior bleeding, alcohol 
use and medication usage predisposing to bleeding 
(non- steroidal anti- inflammatory drugs and platelet 
inhibitors). Variables scored on discharge from the ICU, 
discharge from the hospital and 6 and 12 months after 
hospital discharge were only included for all patients with 
new- onset AF documented in the ICU discharge letter. 
The included variables were: the use of an anticoagulant 
(vitamin K oral anticoagulants, non- vitamin K antagonist, 
oral anticoagulant (apixaban, dabigatran, edoxaban or 
rivaroxaban) or a low- molecular- weight heparin with a 
daily dose >7600 I.E.), use of medication for rate and/
or rhythm control (amiodarone, beta- blocker, digoxin, 
verapamil) and whether the patient was in sinus rhythm.
statistical analyses
Descriptive analysis for patient characteristics included 
mean±SD or median and range for normal and non- 
normally distributed data, respectively. Categorical data 
were described as number and percentage. Kaplan- 
Meier survival curves were used to estimate the median 
survival for the following status categories: (1) no AF, 
(2) known AF, (3) new- onset AF patients. Patients that 
died in the hospital were excluded from the survival anal-
ysis and are listed separately. For new- onset AF patients, 
subanalyses were performed on 1- year survival based on 
AF status. Status categories were 1:1 matched with new- 
onset patients using the APACHE III (Acute Physiology 


















3Jacobs MS, et al. Open Heart 2020;7:e001226. doi:10.1136/openhrt-2019-001226
Arrhythmias and sudden death








(n=583) New- onset AF* (n=213)
Age, median (range) 69 (12–99) 67†‡ (12–99) 7† (31–99) 76‡ (41–97)
Female, n (%) 1426 (42.8)   1100 (43.3)   251 (43.1) 75 (35.2)
APACHE II, median (range) 15 (1–50) 14‡† (1–50) 18†§ (3–44) 19‡§ (5–46)
APACHE III median (range) 57 (6–200) 52‡† (6–200) 70†§ (17–182) 75‡§ (26–191)
LOS ICU, median (range) 2 (0.1–100) 2‡† (0.1–85) 2†§ (0.1–100) 7‡§ (0.3–95)
LOS hospital, median (range) 10 (0.1–196) 9‡† (0.1–128) 11†§ (0.1–196) 16‡§ (0.3–96)
Reason for ICU admission, n (%)         
  Medical 1834 (55.0) 1358‡† (53.5) 345†‡§ (59.2) 131‡§ (62.7)
  Urgent surgery 493 (14.8) 354‡† (14.0) 92†‡§ (15.8) 47‡§ (22.5)
  Planned surgery 1001 (30.0) 824‡† (32.5) 146†‡§ (25.0) 31‡§ (14.8)
Missing   2 (<0.01)   4 (1.2)
*The group 'new- onset AF’ includes documented and non- documented AF.
†Significant difference between no AF group and known AF group (p<0.05).
‡Significant difference between new- onset AF group and no AF group (p<0.05).
§Significant difference between new- onset AF group and known AF group (p<0.05).
AF, atrial fibrillation; APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; LOS, length of stay.
(match tolerance 0.001). The APACHE III score was used 
for propensity score matching to balance the groups 
on survival since this score has a good performance 
to predict mortality. Mean survival was compared for 
different status categories using the log- rank test at a two- 
sided statistical significance level of p=0.05. An explora-
tory analysis was performed to determine if there were 
differences in characteristics between the new- onset AF 
patients in whom anticoagulation was initiated and the 
patients in whom anticoagulation was not started before 
hospital discharge. Comparison was performed with 
an independent samples t- test at a two- sided statistical 
significance level of p=0.10, categorical variables were 
compared using a χ2 test. A multiple logistic regression 
analysis on mortality could be performed if there were 
significant differences (p<0.10) in patient characteristics 
between the two new- onset AF groups based on anticoag-
ulation status.
Results
A total of 3334 unique patients were identified with an 
ICU admission between 1st of January 2011 and 31st of 
December 2016. In 2538 patients (76.1%) there was no 
AF documented. A total of 796 patients (23.9%) had 
any form of AF. AF was already known in 17.5% of the 
patients, and 6.4% (n=213) had new onset AF during the 
ICU admission. In 1.6% (n=54) of the patients, new- onset 
AF was not documented in the ICU discharge letter, and 
reasons for starting or withholding anticoagulation could 
not be retrieved. All patient numbers are summarised in 
online supplementary figure 1.
The median age of the total population was 69 years 
and 42.8% was female. The median length of stay (LOS) 
at the ICU was 2 days for the overall population and 
median total hospital LOS was 10 days. The majority 
of the patients (55%) were admitted to the ICU for a 
medical reason. Table 1 shows that the three groups of 
AF patients had significant differences in patient char-
acteristics. Patients with new- onset AF more often had a 
medical indication for ICU admission, longer LOS at the 
ICU, longer LOS at the hospital, a higher APACHE II and 
III score compared with the other two patient groups. 
Patients with known AF and new- onset AF were older 
than patients with no AF.
treatment strategies for atrial fibrillation: anticoagulation and 
rate/rhythm control
Based on the CHA2DS2- VASsc score, stroke prevention was 
indicated in 94.3% of the patients with new- onset AF and 
only 25.3% of these eligible patients received anticoagu-
lation during their ICU stay. At hospital discharge, 56.3% 
of the eligible patients received an anticoagulant. There 
were also seven patients (5.2%) that were initiated on 
antiplatelet therapy for their AF before being leaving the 
hospital. There were no differences in key patient char-
acteristics between the new- onset AF patient group that 
initiated an anticoagulant before hospital discharge and 
the new- onset patients that did not initiate an anticoag-
ulant (tested variables: age, sex category, reason for ICU 
admission (medical versus surgical), ICU LOS, APACHE 
III score, mean CHA2DS2- VASc score and mean HAS- 
BLED score). When discharged from the ICU, 39.6% of 
the patients still had AF with 55.1% using rate/rhythm 
control medication. Almost half of the patients had an 
unknown rhythm at hospital discharge, and in 60.7% of 
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Table 2 Atrial fibrillation treatment strategy in rate/rhythm 
control and anticoagulant use at the intensive care unit and 
at hospital discharge for new- onset atrial fibrillation patients 
with AF documented in the discharge letter (n=159)
Characteristic
CHA2DS2- VASc score, median (95% CI) 3 (3 to 4)
HAS- BLED score, median (95% CI) 2 (2 to 3)
Rhythm/rate control, n (%)
  Initiated at the ICU (n=159)
   Amiodarone IV administered 109 (68.6)
   Digoxin administered 142 (89.3)
   Verapamil administered 0 (0.0)
   Beta- blocker administered 50 (31.4)
    Oral rate/rhythm control medication at ICU 
discharge*
87 (55.1)
    AF unresolved 63 (39.6)
  Hospital discharge (n=135)
   Rhythm/rate control medication 87 (64.4)
    AF unresolved 82 (60.7)
    Unknown rhythm 63 (46.7)
Anticoagulant initiated, n (total %; % of eligible patients)
  Initiated at the ICU (n=159) 43 (27.0; 25.3)
   Therapeutic LMWH 36 (22.6)
   VKA 5 (3.1)
   NOAC 2 (1.3)
  Hospital discharge (n=135) 68 (50.4; 56.3)
   Therapeutic dose LMWH 7 (5.2)
   VKA 38 (28.1)
   NOAC 23 (17.0)
  One year after hospital discharge (n=99) 36 (36.4; 38.3)
*Oral rate/rhythm control included: amiodarone, beta- blockers, 
digoxin, verapamil.
AF, atrial fibrillation; ICU, intensive care unit; IV, intravenously; 
LMWH, low- molecular- weight heparin; NOAC, non- vitamin K 
antagonist oral anticoagulant; VKA, vitamin K oral antagonist.
AF while 64.4% of patients were using rate/rhythm 
control drugs at discharge. The results for the new- onset 
AF patients are summarised in table 2.
Mortality
In- hospital mortality was 9.8%, 18.9% and 20.3% within 
the subpopulation with no AF, with known AF and with 
new- onset AF. The median follow- up was 1431 days. 
Total mortality during the whole follow- up, including 
in- hospital mortality, was 35.3%, 57.1% and 57.3% in the 
subpopulation with no AF, with known AF and with new- 
onset AF, respectively. One- year mortality, not including 
in- hospital mortality, was 13.5%, 25.0% and 26.0% in the 
subpopulation with no AF, with known AF and with new- 
onset AF, respectively (see figure 1).
Propensity score matching was applied to balance 
the groups of new- onset AF, known AF and no AF with 
regard to the predicted mortality (see Method section). 
The groups were propensity score matched on APACHE 
III score. Patient characteristics of the matched groups 
are summarised in table 3. The median APACHE III 
and range are more balanced compared with the total 
subpopulation (see table 1).
In the propensity matched groups, the in- hospital 
mortality was 5.3% for patients with no AF and 7.2% in 
the patients with known AF. The in- hospital mortality 
for the new- onset AF group was the same as previously 
mentioned (20.3%) since the whole group is used in 
the propensity score matching. The mortality within the 
first year after being discharged from the hospital alive 
was 4.6% in patients with no AF, 11.6% in the patients 
with known AF and 26.0% in patients with new- onset AF 
(Figure 2).
The unadjusted estimated mean survival within the 
total study period was 1334 days for all patients, median 
survival was 1603 days. For the patients with no AF this 
estimated mean survival was 1433 days, 975 days for 
patients with known AF and for new- onset AF patient 
the estimated mean survival was 1033 days. When also 
adding in- hospital mortality to the overall survival curve, 
the mortality rate was proportional in all groups and 
converged after approximately 5 years of follow- up (see 
online supplementary figure 2). In- hospital mortality 
was significantly higher in patients with any form of AF 
compared with patients with no AF (p<0.01, survival curve 
not shown). In- hospital mortality was significantly higher 
for new- onset AF patients compared with patients with 
no AF (p<0.01) but not higher compared with patients 
with known AF (p=0.658) for the non- matched groups. In 
the propensity matched groups, in- hospital mortality was 
significantly higher in the new- onset AF group compared 
with no AF and known AF (both p<0.01).
Mean survival for patients with no AF, with known AF 
and new- onset AF was 347 days, 336 days and 295 days, 
respectively, when censored at a maximum of 360 days. 
Survival was significantly different for these groups 
(p<0.01). Survival was significantly different for no AF 
versus new- onset AF groups (p<0.01). Mean survival in 
new- onset AF patients that was documented during ICU 
admission was not significantly different for patients that 
used an anticoagulant (301 days) or those who did not 
use an anticoagulant (293 days) when discharged from 
the hospital (p=0.701).
dIsCussIOn
The incidence of new- onset AF in the critically ill 
patients admitted to the ICU was 6.4% in this study. 
The incidence found was comparable to other studies, 
where incidence was generally estimated around 5%.4–7 
Stroke prevention was indicated in almost 95% of the 
newly diagnosed AF patients based on the stroke risk 
although only 26.7% of these eligible patients received 
anticoagulation during their ICU stay. At hospital 
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Figure 1 Survival censored at 360 days of follow- up after hospital discharge for all patients (n=3334), stratified by all atrial 
fibrillation category. A vertical line in the curve represents a censored patient. AF, atrial fibrillation.
Table 3 Subgroup patient characteristics of intensive care 
unit admitted patients by subgroups within the period 2011 









Age, median (range) 70 (20–93) 76 (31–94) 76 (41–97)
Female, n (%) 90 (43.2) 90 (46.2) 75 (35.2)
APACHE II, median (range) 18 (3–49) 18 (7–44) 19 (5–46)
APACHE III, median (range) 75 (25–191) 74 (26–126) 75 (26–191)
LOS ICU, median (range) 3 (0.2–76.4) 3 (0.1–100) 7 (0.3–95)
LOS hospital, median (range) 13 (0.1–128) 13 (0.1–196) 16 (0.3–96)
New- onset AF includes documented and non- documented AF.
AF, atrial fibrillation; APACHE, Acute Physiology and Chronic Health 
Evaluation; ICU, intensive care unit; LOS, length of stay.
anticoagulant. Reasons not to initiate anticoagulation 
included poor prognosis, recent surgery with perceived 
increased risk of bleeding or postponement to the 
post- hospitalisation period for a cardiologist to decide. 
Although this was not studied, an epidural could also 
be a reason to postpone anticoagulation. There were 
no clear differences in patient characteristics between 
patient in whom anticoagulation was started versus 
those who did not receive anticoagulants. This illus-
trates the lack of evidence and guidance on treatment 
in this specific patient group of critically ill new- onset 
AF patients. Other studies also reported percentages of 
70.4% and 69.6% for AF patients that did not receive 
anticoagulation at the ICU.3 12
Spontaneous restoration of normal sinus rhythm was 
mentioned as a reason not to initiate any anticoagulant 
therapy. Often this was the case if the duration of the 
arrhythmia was limited to less than 1 day. The percep-
tion seems to exist that the need of anticoagulation 
depends on a patient’s symptomatic status. In general, 
evidence suggests that the stroke risk is still increased 
after restoration of sinus rhythm.8 14 15 However, it can 
be debated if this principle also applies to AF that 
developed in the critically ill phase since there could 
be provoking factors for developing an arrhythmia.5 10 
A recent study showed that there was no difference 
in stroke occurrence after 5 years follow- up between 
patients with new- onset postoperative AF following 
coronary artery bypass grafting (CABG) and patients 
without new- onset postoperative AF following CABG.16 
Another study found that the thromboembolic risk was 
lower in post- CABG new- onset AF patients compared 
with matched non- valvular AF patients (HR 0.67; 
95% CI 0.55 to 0.81). The risk of thromboembolism was 
also not significantly higher in patients with postopera-
tive new- onset AF compared with patients that did not 
develop AF after CABG surgery.17 These findings might 
indicate that the thromboembolic risk of new- onset AF 
patients shouldn’t be regarded equivalent to the risk 
of non- valvular AF patients. Sinus rhythm was restored 
in 60% of the patients at discharge from the ICU, this 
dropped to around 40% at hospital discharge though 
this could be an underestimate since the rhythm was 
unknown in around half of the discharged patients. 
The percentage of patients that left the ICU in sinus 
rhythm is comparable to another study that found 82% 
of the patients in sinus rhythm.6 In- hospital mortality 
in our study population was comparable to results 
found in other ICU studies.12 18 19 Also, overall mortality 
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Figure 2 Survival censored at 360 days of follow- up after hospital discharge compared with propensity score matched 
groups of patients with no atrial fibrillation or known atrial fibrillation or versus patients with new- onset atrial fibrillation (n=208, 
n=195 and n=213, respectively). A vertical line in the curve represents a censored patient. AF, atrial fibrillation.
New- onset AF patients had a lower survival compared 
with patients with no AF or previously diagnosed AF, also 
after propensity score matching. AF is often found to 
be an (independent) predictor of mortality in critically 
ill patients.7 12 15 20 Whether the association between AF 
and hospital mortality is independent could be debated 
since many factors can influence mortality.8 New- onset 
AF patients often have a higher LOS and severe sepsis 
occurs more often.8 12 21
Our study was a single centre study and therefore 
the results are not by definition representative of a 
general ICU population. Patient characteristics could 
be diverse between different ICUs also depending on 
the type of ICU (medical or surgical). However, when 
comparing the results of our ICU to that of other Dutch 
ICUs we found similar results with regard to mortality.19 
Also, the new- onset AF prevalence was comparable to 
that found in other ICU studies.4–7 Data was retrospec-
tively collected, therefore data can be incomplete and 
there could be a lack of documentation of AF since 
data collection was not designed for this research ques-
tion. The number of patients with new- onset AF was too 
small to determine the influence of anticoagulation 
on survival. This analysis should be considered as an 
explanatory analysis that was underpowered to draw 
any firm conclusions. Larger cohorts are needed to 
see what effect anticoagulation has on mortality and 
stroke. A final answer on the question whether critically 
ill patients with new onset AF require anticoagulation 
therapy should come from a randomised controlled 
clinical trial. Assuming stroke prevention could reduce 
mortality by 25%, a power of 80% and 15% mortality in 
the control group, based on numbers for Dutch ICUs, 
at a significance level of 0.05, you would need over 
1250 patients with new onset AF in both arms of this 
study.17 Based on an incidence of 5% of new onset AF, 
this would require an initial data set of 50 000 admitted 
ICU patients.
COnClusIOn
New- onset AF in critically ill patients is associated with a 
higher mortality compared with patients with no AF or 
previously diagnosed AF. There was no effect found for 
anticoagulative status on mortality based on the results 
of an exploratory analysis. AF treatment in terms of anti-
coagulation is not well defined in clinical guidelines 
and this is reflected in the results that showed less than 
60% of the eligible new- onset AF patients, based on the 
calculated stroke risk, received anticoagulation before 
hospital discharge. More evidence is needed to optimise 
treatment in this specific population and to highlight the 
importance on long- term outcomes such as mortality and 
stroke.
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